Belimumab, A BLyS-Specific Inhibitor, Reduced Disease Activity, Flares and Prednisone Use in Patients with Active SLE: Efficacy and Safety Results From the Phase 3 BLISS-52 Study.

¹U of Sto Tomas Hosp, Mla, Philippines, ²Bogota, Colombia, ³HBBA, Buenos Aires, Argentina, ⁴Univ do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁵Chinese U of HK, Hong Kong, China, ⁶Kerala Inst of Med Sci, Trivandrum, India, ⁷Hosp Dr Gustavo Fricke, Vina del Mar, Chile, ⁸Inst de Ginec y Rep, Lima, Peru, ⁹Emeritus Res-Cabrini Hosp, Malvern, Australia, ¹⁰Veterans Gen Hosp, Taiching, Taiwan, ¹¹Institute of Rheumatology, Moscow, Russia, ¹²Spitalul Clin Colentina, Bucharest, Romania, ¹³Catholic U of Korea St Mary's Hosp, Seoul, South Korea, ¹⁴HGS, Rockville, MD, ¹⁵Johns Hopkins U, Baltimore, MD